Pharmaceuticals News and Research

RSS

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

28 Oct 2011

Virtual platform for intellectual property sharing aims to speed development of drug treatments

"The World Intellectual Property Organization (WIPO) launched a consortium on Wednesday that would allow the public and private sector to share intellectual property to promote the development of new drugs to treat diseases such as malaria," Reuters reports.

28 Oct 2011

Gilead submits Quad NDA to FDA for treatment of HIV-1 infection

Gilead Sciences, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the "Quad", a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.

28 Oct 2011

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Regeneron Pharmaceuticals, Inc. today announced that detailed clinical data from the positive Phase 2b portion of the seamless Phase 2/3 MOBILITY trial of sarilumab in rheumatoid arthritis (RA) will be presented at a late-breaking poster session at the upcoming American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place from November 5-9 in Chicago.

28 Oct 2011

Bottom-line boost for Australian Biotechs

Biotechnology companies and international investors are reporting excellent results from this year’s AusBiotech conference, with programs and activities dedicated to helping companies and researchers connect with investors and partners, stirring substantial international interest.

27 Oct 2011

Mylan receives final FDA approval for Morphine Sulfate ER Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Morphine Sulfate Extended-release (ER) Tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.

27 Oct 2011

ICON third quarter net revenues increase 7% to $241 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2011.

27 Oct 2011

Nanoparticles could help increase retention of osteoarthritis drugs in knee cavity

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive.

27 Oct 2011

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

27 Oct 2011

New potential leukemia therapy targets and kills cancer cells

A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone. Many current chemotherapy treatments affect cancer cells and healthy cells, causing significant side effects, such as fatigue, hair loss, nausea, anxiety and depression.

27 Oct 2011

Addressing barriers to successful immunization programs important while vaccine development progresses

Immunizations can be a cost-effective means of disease prevention, but "[t]o reach the fully realized stage of cost-effectiveness, ... it is vital to acknowledge -- and more importantly, address -- the barriers that often prevent them from either being as cheap or as widely used as needed," Forbes contributor Sarika Bansal writes in a Forbes opinion piece.

27 Oct 2011

Biogen’s Multiple Sclerosis pill succeeds at a late phase clinical trial

Biogen Idec Inc. has reported success in a late stage clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva Pharmaceutical Industries’ Laquinimod. A 240-milligram dose of BG-12 administered two or three times a day significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively, after two years compared with a placebo.

24 Oct 2011

Your medical privacy – Another Obamacare casualty

It was a sad day recently when a married menopausal woman learned that her recent Pap test was positive for human papilloma virus (HPV). “How could this happen?” she asked. “I have not had relations with anyone but my husband since we married 30 years ago.”

24 Oct 2011

Taconic and Oncodesign announce agreement to co-promote and co-develop solutions to advance oncology research

Taconic, a leading provider of life sciences solutions, and Oncodesign(R), an innovative leader in the discovery of novel anti-cancer therapies, announce today that they have entered into an agreement to co-develop and co-promote pre-clinical oncology in vivo solutions for researchers worldwide. The agreement provides researchers with improved access to a large, diverse portfolio of translational models for use in pre-clinical oncology studies, along with supporting scientific services.

24 Oct 2011

Bio-Images and Medimetrics partner to deliver the next generation of smart pill technology

Bio-Images Research and Medimetrics Personalized Drug Delivery have today announced a partnership to introduce the IntelliCap to the global pharmaceutical industry as a clinical research tool. The announcement was made at the annual meeting of the American Association of Pharmaceutical Scientists, being held in Washington DC, USA, between 23 and 27 October 2011.

24 Oct 2011

Co-branded newsletter for contract research organization industry launched

CenterWatch and Plutus Capital Partners today announce the launch of Clinical Trials Quarterly, a co-branded newsletter for the contract research organization (CRO) industry that expands CenterWatch's reach to financial clients in Asia and Europe.

24 Oct 2011

Holes appearing in some states' safety nets for disabled, seniors; Ohio referendum looms

Health care news from Georgia, Ohio, California, Wisconsin, Florida, Iowa, Massachusetts and Texas.

24 Oct 2011

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

Pharmaceutical company Pharmaxis today announced the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care."

24 Oct 2011

Comprehensive ADMESeq Research Screening Panel launched

RainDance Technologies, Inc., the Digital Biology Company, and Ambry Genetics, today announced the launch of a comprehensive targeted sequencing panel to screen genes involved with drug absorption, distribution, metabolism, and excretion (ADME) research. The ADMESeq Research Screening Panel enables researchers to simultaneously interrogate 242 known pharmacogenetic genes using next-generation sequencing (NGS) systems.

24 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

Pharmaceuticals News and Research

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Virtual platform for intellectual property sharing aims to speed development of drug treatments

Gilead submits Quad NDA to FDA for treatment of HIV-1 infection

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Bottom-line boost for Australian Biotechs

Mylan receives final FDA approval for Morphine Sulfate ER Tablets ANDA

ICON third quarter net revenues increase 7% to $241 million

Nanoparticles could help increase retention of osteoarthritis drugs in knee cavity

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

New potential leukemia therapy targets and kills cancer cells

Addressing barriers to successful immunization programs important while vaccine development progresses

Biogen’s Multiple Sclerosis pill succeeds at a late phase clinical trial

Your medical privacy – Another Obamacare casualty

Taconic and Oncodesign announce agreement to co-promote and co-develop solutions to advance oncology research

Bio-Images and Medimetrics partner to deliver the next generation of smart pill technology

Co-branded newsletter for contract research organization industry launched

Holes appearing in some states' safety nets for disabled, seniors; Ohio referendum looms

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

Comprehensive ADMESeq Research Screening Panel launched

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence